Efficacy of indacaterol 75 μg once-daily on dyspnea and health status: Results of two double-blind, placebo-controlled 12-week studies

COPD: Journal of Chronic Obstructive Pulmonary Disease

Volumn 9, Issue 6, 2012, Pages 629-636

  Gotfried, Mark H ^a   Kerwin, Edward M ^b   Lawrence, David ^c   Lassen, Cheryl ^c   Kramer, Benjamin ^d  

^a Pulmonary Associates   (United States)

^b Clinical Research Institute of Southern Oregon   (United States)

^c NOVARTIS HORSHAM RESEARCH CENTRE   (United Kingdom)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Randomized clinical trial; St George's Respiratory Questionnaire; Symptoms; Transition dyspnea index

Indexed keywords

INDACATEROL; PLACEBO;

ADULT; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; ST. GEORGE RESPIRATORY QUESTIONNAIRE; TRANSITION DYSPNEA INDEX; TREATMENT DURATION; TREATMENT OUTCOME; UNITED STATES;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-2 RECEPTOR AGONISTS; AGED; ANALYSIS OF VARIANCE; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; HEALTH STATUS INDICATORS; HUMANS; INDANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUESTIONNAIRES; QUINOLONES; TREATMENT OUTCOME;

EID: 84871504776     PISSN: 15412555     EISSN: 15412563     Source Type: Journal    
DOI: 10.3109/15412555.2012.729623     Document Type: Article

References (19)

1. Global Initiative For Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of chronic obstructive pulmonary disease. Updated 2011. At: www.goldcopd.com [accessed 15 March 2012].
2. Feldman G, Siler T, Prasad N, Jack D, Piggott S, Owen R, et al. Efficacy and safety of indacaterol 150 μg once-daily in COPD: a double-blind, randomised, 12-week study. BMC Pulm Med 2010; 10:11.
3. Donohue JF, Fogarty C, Lotvall J, Mahler DA, Worth H, Yorgancioglu A, et al. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med 2010; 182(2):155-162.
4. Kornmann O, Dahl R, Centanni S, Dogra A, Owen R, Lassen C, et al. Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur Respir J 2011; 37(2):273-279.
5. Dahl R, Chung KF, Buhl R, Magnussen H, Nonikov V, Jack D, et al. Efficacy of a new once-daily long-acting inhaled β2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax 2010; 65(6):473-479.
6. Chapman KR, Rennard SI, Dogra A, Owen R, Lassen C, Kramer B, et al. Long-term safety and Efficacy of indacaterol, a long-acting β-agonist, in subjects with COPD: a randomized, placebo-controlled study. Chest 2011; 140(1):68-75.
7. Barnes PJ, Pocock SJ, Magnussen H, Iqbal A, Kramer B, Higgins M, et al. Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design.Pulm Pharmacol Ther 2010; 23(3):165-171.
8. Kerwin EM, Gotfried MH, Lawrence D, Lassen C, Kramer B. Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies. Clin Ther 2011; 33(12):1974-1984.
9. Global Initiative For Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Updated 2008. At: www.goldcopd.com [accessed 1 February 2012].
10. Mahler DA, Weinberg DH, Wells CK, Feinstein AR. The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 1984; 85(6):751-758.
11. Witek TJ Jr, Mahler DA. Meaningful Effect size and patterns of response of the transition dyspnea index. J Clin Epidemiol 2003; 56(3):248-255.
12. Witek TJ Jr, Mahler DA. Minimal important diff erence of the transition dyspnoea index in a multinational clinical trial. Eur Respir J 2003; 21(2):267-272.
13. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A selfcomplete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis 1992; 145(6):1321-1327. PubMed PMID: 1595997.
14. Jones PW. St. George's Respiratory Questionnaire: MCID. COPD 2005; 2(1):75-79.
15. Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, et al. The body-mass index, airfl ow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004; 350(10):1005-1012.
16. Williams M, Cafarella P, Olds T, Petkov J, Frith P. Aff ective descriptors of the sensation of breathlessness are more highly associated with severity of impairment than physical descriptors in people with COPD. Chest 2010; 138(2):315-322.
17. Ries AL. Impact of chronic obstructive pulmonary disease on quality of life: the role of dyspnea. Am J Med 2006; 119(10 Suppl 1):12-20.
18. Jones PW, Barnes N, Vogelmeier C, Lawrence D, Kramer B. Efficacy of indacaterol in the treatment of patients with COPD. Prim Care Respir J 2011; 20(4):380-388.
19. Donohue JF, Singh D, Kornmann O, Lawrence D, Lassen C, Kramer B. Safety of indacaterol in the treatment of patients with COPD. Int J Chron Obstruct Pulmon Dis 2011; 6:477- 492